Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 17 Prostatic Neoplasms 6 Ovarian Neoplasms 6 Neoplasms 5 Triple Negative Breast Neoplasms 4 Neoplasm Metastasis 4 Stomach Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Solid Tumors 2 Multiple Myeloma 2 Mouth Neoplasms 2 Lymphoma 2 Laryngeal Neoplasms 2 Hypopharyngeal Neoplasms 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Carcinoma 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Cancers 1 Skin Diseases 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Pancreatic Neoplasms 1 Oropharyngeal Neoplasms 1

Interventions

Oxaliplatin 46 Gemcitabine 45 Fluorouracil 40 Capecitabine 31 pembrolizumab 29 Leucovorin 29 Docetaxel 27 Cisplatin 25 Paclitaxel 23 Irinotecan 18 Carboplatin 18 Bevacizumab 18 130-nm albumin-bound paclitaxel 17 Pemetrexed 15 Albumin-Bound Paclitaxel 15 Radiotherapy 14 Nivolumab 12 Ramucirumab 11 Cyclophosphamide 11 Trastuzumab 8 Erlotinib Hydrochloride 8 Taxes 7 Radiosurgery 7 Drug Therapy 7 cemiplimab 6 zolbetuximab 5 trastuzumab deruxtecan 5 regorafenib 5 durvalumab 5 Sorafenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenocarcinoma × ipatasertib × Clear all

NCT04739202 2026-06-09

IMMUNOGAST

Hospices Civils de Lyon

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡